Table 2. Discounted rubella vaccination costs, CRS cases, treatment costs, net Costs, DALYs averted and cost per DALY averted in 2018 US$ over 2018–2047, 93 LMICs.
| Discounted rubella vaccination costs, treatment costs, net costs and DALYs averted | |||||
|---|---|---|---|---|---|
| Scenario | Discounted*vaccination costs(millions) | CRS cases (000 s) | CRStreatment costs(millions) | DALYs(millions) | Total costs(millions) |
| Base Case | US$2908 | 892 | US$3980 | 23.8 | US$6887 |
| Continuing Trends | US$4473 | 252 | US$1457 | 6.6 | US$5931 |
| Constant Improvement | US$4113 | 298 | US$1746 | 7.8 | US$5859 |
| Intensified Investment | US$4611 | 223 | US$1296 | 5.9 | US$5907 |
| Cost per DALY averted | ||||
|---|---|---|---|---|
| Scenario | Comparator | Net Costs (millions) | DALYs averted(millions) | Cost per DALY averted |
| Continuing Trends | Base Case | −US$420.8 | 9.8 | Dominant |
| Constant Improvement | Continuing Trends | US$6.4 | 1.2 | US$5.3 |
| Intensified Investment | Continuing Trends | US$47.6 | 1.6 | US$29.3 |
| Intensified Investment | Constant Improvement | US$41.1 | 0.4 | US$101.3 |
*
The costs were discounted with a discount rate of 3%. Note: the cost-effectiveness threshold for the 92 LMICs, were estimated based on cost per DALYs averted that reflect health opportunity costs on mortality of changes in health expenditures.13
DALYs, disability-adjusted life years; LMICs, low-income and middle-income countries.